Form 8-K - Current report:
SEC Accession No. 0001367644-24-000058
Filing Date
2024-05-01
Accepted
2024-05-01 16:05:22
Documents
15
Period of Report
2024-05-01
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ebs-20240501.htm   iXBRL 8-K 33199
2 EX-99.1 ebsnewtrelease.htm EX-99.1 14651
6 image.jpg GRAPHIC 7489
  Complete submission text file 0001367644-24-000058.txt   191002

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ebs-20240501.xsd EX-101.SCH 1967
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ebs-20240501_lab.xml EX-101.LAB 22804
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ebs-20240501_pre.xml EX-101.PRE 13102
18 EXTRACTED XBRL INSTANCE DOCUMENT ebs-20240501_htm.xml XML 2819
Mailing Address 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879
Business Address 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879 240-631-3200
Emergent BioSolutions Inc. (Filer) CIK: 0001367644 (see all company filings)

EIN.: 141902018 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33137 | Film No.: 24902918
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)